美国临床实验室服务市场成长机会及至2030年预测

受专业检测的扩展、数位化工作流程创新以及对基于价值的医疗服务的需求推动。

由于美国人口老化、患者对检测益处的认识提高、检测成本下降、用于疾病检测和管理的先进和专业检测方法的开发、人们越来越意识到早期检测和预防是降低医疗保健成本的一种手段，以及遗传学、基因组学和个性化医疗领域的持续研究和开发，临床检测行业预计将继续经历检测量的增加。

美国医疗保健支出约占其GDP的18%。医疗保健价值链上的参与者面临着受多种趋势影响的动态环境，包括人口老化、慢性病负担加重、监管挑战、整个医疗保健链的整合、向基于价值和责任医疗模式的转变、支付方与提供方的整合、数据获取管道的更新和扩展、创新和技术，以及消费者参与度和期望值的提高。

在疫情后检测需求正常化、门诊病人增加以及先进的分子和基因组检测融入常规诊疗的推动下，2024年和2025年的增长势头将持续加速。从2026年开始，随着支付方主导的使用限制和高通量效率的逐步落实，预计成长速度将放缓至4-5%左右，与更新后的预测轨迹相符。儘管《保护医疗保险取得法案》（PAMA）带来的价格压力仍然存在，但支付方的报销越来越与临床效用和检测价值挂钩。为了确保获利能力，实验室（尤其是医院附属实验室和中型区域实验室）被迫专注于营运扩充性、检测专案优化和数位化工作流程效率的提升，以维持盈利。

报告摘要：美国医疗和诊断检测服务市场

美国医疗和诊断检测服务市场预计在2024年达到1308.8亿美元，到2030年将达到1751.3亿美元，2024年至2030年的复合年增长率为5.0%。市场成长的驱动因素包括人口老化导致检测量增加、慢性病盛行率上升以及实验室诊断在预防保健和基于价值的医疗保健模式中的作用日益增强。

关键市场趋势与洞察

• 在全国物流网路和各种检测项目的支持下，独立实验室和参考实验室在临床实验室服务市场中占据了巨大的检测量。
• 美国临床实验室服务市场对常规诊断测试以及分子诊断、肿瘤检测和基因检测的需求不断增长。
• 自动化、LIS-EHR 整合和 AI 驱动的工作流程最佳化正在提高大中型实验室的检测结果报告时间和营运效率。
• 美国临床实验室服务市场正在经历持续的整合，大规模国家实验室寻求透过收购和加强与医院的合作来扩大业务。
• 零售诊所、行动诊断和家庭检体采集模式正在扩大患者的就医途径和便利性，从而支持提高检测利用率。

市场规模及预测

• 2024年市场规模：1,308.8亿美元
• 2030年市场规模预测：1751.3亿美元
• 复合年增长率（2024-2030年）：5.0%
• 美国：拥有全国性检测网路的单一市场

美国医疗保健系统对诊断测试的持续依赖，以及技术应用和服务模式的创新，预计将在整个预测期内支持美国医疗和诊断测试服务市场的持续成长。

市场概览及趋势：美国医疗与诊断检测服务市场

美国医疗和诊断检测服务市场几乎贯穿整个医疗保健流程的每项临床决策。检测有助于筛检、诊断、治疗方案选择和疾病监测，这使得临床实验室服务市场成为现代医疗保健不可或缺的一部分。由于人口老化、慢性病负担加重以及基于价值的医疗模式下诊断检测的广泛应用，市场需求持续增长。

塑造美国临床实验室服务市场的一个关键结构性趋势是转向专业化和高度复杂的检测方向。分子诊断、基因组学、肿瘤检测和伴随诊断越来越多地被用于指南个人化治疗策略。常规检测的检测量保持稳定，而专业诊断则推动了检测量的增量增长和临床相关性的提升。

自动化数位化正在改变实验室的运作方式。先进的机器人技术、实验室资讯系统 (LIS) 和人工智慧驱动的工作流程工具正在加快检测结果的周转速度，并减少对人工的依赖。鑑于美国医疗和诊断检测服务市场持续面临劳动力短缺，这些投资显得尤为重要。

另一个重要趋势是检测的集中化。由于规模经济和更广泛的检测项目，独立检测机构和参考实验室正在占据越来越多的外包检测份额。虽然整合带来了成本效益，但也加剧了美国临床实验室服务市场的竞争。

医疗保健的消费化也正在影响需求。零售诊所、行动诊断和居家检体采集正在扩大常规检测和预防性护理的覆盖范围。这些模式是对传统医院服务的补充，并正在重塑临床实验室服务市场的病患参与模式。

总体而言，市场正在朝着更自动化、数据驱动和以患者为中心的诊断生态系统发展。

分析范围：美国医疗与诊断检测服务市场

本分析检验了美国医疗和诊断测试服务市场，重点关注美国境内提供的实验室测试服务。本研究评估了对血液、组织、尿液和其他生物检体进行的诊断测试，以支持预防、诊断和治疗领域的临床决策。

报告涵盖医院检查室、独立实验室和参考实验室、医生诊所检查室，以及新兴的零售和居家检测模式。美国临床实验室服务市场包括常规检测和特殊检测服务，但不包括检测设备製造和试剂销售。

本研究涵盖近几年至2030年，以2024年为基准年，2030年为预测终点。市场规模和预测均以美元计价。

调查方法整合了二手研究、医疗服务使用资料、监管审查和专家意见。我们的市场预测反映了检测量趋势、报销趋势以及整体临床实验室服务市场的结构性变化。为了保持分析的一致性，我们刻意不提供按细分市场分類的收入预测。

市场区隔分析：美国医疗与诊断检测服务市场

美国医疗和诊断检测服务市场按提供者类型和检测服务类别进行细分，反映了更广泛的临床检测服务市场中多样化的营运模式和临床角色。

按服务提供者进行细分

按提供者类型划分，美国临床检测服务检查室包括医院检查室、医生拥有的检查室(POL)、独立实验室和参考检查室、专业检查室和其他检测机构。

院内检查室处理最大的检测量，并直接整合到医院系统中，为住院患者照护、急诊诊断和复杂的临床工作流程提供支援。这些检查室通常隶属于大规模医疗机构或大学附属医院，因此能够快速出具检测结果并与临床团队密切合作。

医生自营检查室（POL）设在医生诊所和专科诊所内，例如泌尿系统、妇科和内分泌科。虽然以机构数量计算，POL是最常见的检查室类型，但其检测量仅占总检测量的不到10%。这些机构专注于小批量常规检测和就地检验，可即时获得结果。大规模的POL网路通常会将检体送到中心检查室进行更进阶的检测。

独立实验室、参考实验室和专业实验室的业务范围遍及广阔的地域，并管理多个检测设施。参考实验室提供全面的检测项目，并能处理高通量检测；而专业实验室则专注于肿瘤学、遗传学和分子检测等高阶诊断。这些机构在美国临床实验室服务市场中扮演着核心角色，为医院和病患实验室（POL）的外包检测提供支援。

其他检测机构包括零售诊所、行动诊断中心、养老院和居家医疗机构。这些机构主要提供常规和预防性检测。此类服务大多为自费，无法获得联邦医疗保险（Medicare）的全额报销，因此对医疗保健总收入的贡献有限。

检验服务分类

根据服务类型，临床检测服务市场分为常规检测服务和特殊检测服务。

常规检测服务包括常见的诊断程序，如血液化学分析、血液常规检查、尿液检查等。这些检测构成了美国医疗和诊断检测服务市场诊断量的基础。

专业检测服务包括细胞遗传学检测、分子诊断、次世代定序(NGS) 和全EXOME定序(WES) 等高阶诊断技术。血液凝固检验、自体免疫检测和癌症生物标记检测等半专业服务也属于此类。专业检测的成长反映了精准医疗和先进临床决策支援日益增长的需求。

收入与预测：美国医疗与诊断检测服务市场

随着自动化、产业整合以及向价值医疗模式的转变重塑产业经济，美国医疗和诊断检测服务市场持续发展。营收预测显示，该市场规模将在2024年达到1,308.8亿美元，并在2030年达到1,751.3亿美元。这意味着2024年至2030年的年复合成长率（CAGR）为5.0%，展现出稳定扩张的趋势，也印证了检测在美国医疗保健系统临床决策中发挥的关键作用。

美国临床实验室服务市场的收入成长主要受人口老化、慢性病盛行率上升以及预防保健和后续观察中诊断检测应用日益广泛等因素推动，从而导致检测量增加。同时，由于《病患保护与平价医疗法案》(PAMA) 的报销削减、人事费用上升以及对检查室自建检测 (LDT) 的监管审查加强，检查室正经历结构性变革以应对利润压力。

大规模全国性网路实验室和医院附属实验室正透过合併、数位整合和人工智慧驱动的流程自动化加速扩张，以提高营运效率和规模。对自动化、实验室资讯系统 (LIS) 和电子健康记录 (EHR) 整合以及高级分析的投资，使医疗机构能够在控製成本的同时应对不断增长的检测量。此外，居家诊断和直接面向消费者的检测等新的检测管道也促进了收入的成长。

总体而言，临床实验室服务市场仍以高交易量为特征，但收入成长越来越与支付方合作、营运规模和技术采用相关，从而推动美国临床实验室服务市场在预测期结束前持续成长。

成长要素：美国医疗和诊断检测服务市场

美国医疗和诊断检测服务市场受益于多项结构性成长要素，预计这些因素将在整个预测期内维持市场需求。其中一个最重要的驱动因素是临床资讯学和医疗数据生成在早期研究、临床开发和商业诊断领域的快速发展。不断增长的数据量提升了整合诊断、预测分析、决策支援工具和伴随诊断 (CDx) 的价值，从而强化了检查室在药物研发和临床试验中的作用。

医生自营实验室（POL）就地检验（POC​​T）能力的扩展正在加速临床实验室服务市场的技术应用。同时，消费者对远端医疗平台、行动医疗应用和连网诊断设备等健康资讯科技解决方案日益增长的兴趣，也推动了对便利、快速且经济高效的检测服务的需求。

另一个关键成长要素是基于次世代定序（NGS）的检测方法在感染疾病、肿瘤和基因检测领域的持续扩展。保险覆盖范围的扩大和检测成本的下降正推动分子病理学服务的应用实现两位数增长。

营运投资也正在改变美国临床实验室服务市场。对机器人、实验室资讯系统 (LIS) 和电子健康记录 (EHR) 整合以及人工智慧驱动的自动化投入的增加，提高了检查室的吞吐量，同时也缩短了出结果时间并减少了对人工的依赖。端到端的数位化工作流程正成为内部检查室和外部实验室的优先事项。

最后，来自《病患准入与平价医疗法案》(PAMA) 和综合支付模式的持续报销压力正促使检查室向更高价值、以结果为导向的服务模式转型。产业整合和垂直一体化，以及居家采血、行动诊断和零售检测合作的成长，进一步扩大了服务覆盖范围，并推动了美国临床实验室服务市场的持续成长。

成长抑制因素：美国医疗和诊断检测服务市场

美国医疗和诊断检测服务市场面临许多结构性限制因素，这些因素可能会在整个预测期内抑制其成长。其中一项最严峻的挑战是美国食品药物管理局 (FDA) 关于检查室自建检测 (LDT) 的最终规则，该规则将于 2024 年生效。这项法规将增加合规、检验和文件编製成本，对小规模和专业检查室的影响尤其显着。虽然大规模参考检查室可能从中获得相对优势，但学术实验室和医院附属检查室将面临更长的新週期和较慢的检测方法推广速度。

在整个临床实验室服务市场，人才短缺仍然是一个持续存在的阻碍因素。由于培训计画资金不足、人员流动率高以及人才引进有限，美国合格的临床实验室技术人员持续短缺。尤其是在医院检查室，日益严重的职业倦怠、加班成本和人事费用限制了其发展。虽然自动化和外包可以在一定程度上缓解这个问题，但它们无法完全弥补人才短缺。

资本密集度也是一项重大挑战。临床检查室需要持续投资于分析设备、自动化平台和IT基础设施。中小检查室面临利润率低、投资回收期长和资金筹措管道有限等问题，而通货膨胀和报销率下降加剧了这些压力。

此外，儘管电子健康记录 (EHR) 整合已被强制要求，但高级分析和自动化技术的应用仍然滞后。互通性问题、中介软体系统碎片化、资料孤岛、网路安全风险持续阻碍营运效率。缺乏标准化的检测申请和数据交换通讯协定进一步加重了行政负担，导致计费延迟、索赔被拒，以及在多方付费和跨州检查室网路中因违规处罚。

竞争格局：美国医疗与诊断检测服务市场

美国医疗和诊断检测服务市场呈现出高度分散但又日益整合的竞争格局，全国约有1500家获得CLIA认证的实验室，其中包括区域性和全国性独立实验室、医院外包专案、参考实验室和专业检测服务提供者。美国临床检测服务市场的竞争主要受规模、合规性、服务范围和营运效率等因素所驱动。

影响临床实验室服务市场差异化的关键竞争因素包括：是否符合CLIA和CAP标准、支付方的报销率、检测准确性、週转时间、成本效益以及检测项目的广度。与电子健康记录（EHR）系统的整合以及透过收购实现整合协同协同效应的能力，对于竞争定位也至关重要，尤其对于大规模全国性医疗机构而言。

最终用户群包括医院检查室、医生拥有的检查室(POL)、独立实验室和参考实验室以及专业检测提供商，此外，零售诊所、移动诊断中心、疗养院和居家医疗机构也有需求，所有这些都越来越多地融入美国临床实验室服务市场的医疗保健服务模式中。

竞赛模式主要由大规模全国性专业机构主导，例如 Labcorp、Quest Diagnostics、Exact Sciences、Natera、Sonic Healthcare USA、Myriad Genetics、Guardant Health、Mayo Clinic Laboratories 和 ARUP Laboratories。预计到 2024 年，排名前五的独立参考实验室 (IRL) 将占美国临床检测服务总收入的 46.3%，显示市场高端集中度日益提高。

其他值得关注的公司包括 BioReference Laboratories、Northwell Health Labs、PathGroup 和 Aegis Sciences，以及克利夫兰诊所和约翰霍普金斯等学术医院网络。

美国医疗和诊断检测服务市场的分销模式结合了医院网路、集中式参考实验室以及不断扩展的用于检体采集的宅配和数位化物流基础设施。 2024年，Quest Diagnostics收购了Allina Health的部分检测资产，增强了明尼苏达州和威斯康辛州西部地区的检测服务覆盖范围，并凸显了该市场持续整合的趋势。

目录

发展机会：研究范围

• 分析范围
• 分割
• 临床实验室服务在医疗保健中的作用
• 综合经营模式－实验室作为一站式服务提供者
• 创新以增强临床检测服务

成长环境：美国临床实验室服务业的转型

• 为什么经济成长变得越来越困难？
• 策略要务
• 三大策略要务对美国临床实验室服务业的影响

美国临床实验室服务生态系统

• 竞争环境

推动美国临床实验室服务业成长的因素

• 成长指标
• 成长驱动因素
• 成长限制因素
• 预测考量
• 收入预测
• 收入预测分析
• 服务供应商的收入预测
• 服务供应商收入预测分析
• 按服务分類的收入预测
• 按服务分類的收入预测分析
• 美国临床实验室服务定价分析
• 美国临床实验室服务按应用领域分類的定价分析（2024 年）
• 美国化验服务应用份额细分
• 美国监管和报销的关键趋势（2020-2025 年）
• 美国监管环境分析－2024年及以后
• 2024年美国健康保险展望概述
• 联邦医疗保险和医疗补助医院医疗费用支出
• 收益分成
• 收入份额分析－竞争对手
• 按付款人类型分類的 IRL 收入份额
• 主要企业提供的竞争格局和参数
• 重要活动

美国临床实验室服务领域的成长机会

• 增长机会 1：除急性病和肿瘤检测之外的专科和高级检测
• 成长机会2：建构去中心化的居家诊断生态系统，提升诊断的可近性与速度
• 成长机会3：人工智慧驱动的数位病理学和高通量诊断工作流程自动化

附录与后续步骤

Fueled by Specialty Testing Expansion, Digital Workflow Innovation, and Value-Based Healthcare Demands

The clinical laboratory testing industry will continue to experience growth in testing volumes due to the aging of the US population, patient awareness of the benefits of laboratory testing, test cost reductions, the development of advanced and specialized tests for disease detection and management, the growing awareness of early detection and prevention as a way to lower healthcare costs, and continued research and development in genetics, genomics, and personalized medicine.

The United States spends approximately 18% of its GDP on healthcare. Healthcare value chain participants face dynamic environments that several trends impact, including the rise in the aging population, chronic disease burden, regulatory challenges, integration across the care continuum, migration to value-based and accountable care models, payer and provider consolidation, new and increased access to data, innovation, and technology, and increasing levels of consumer engagement and expectations.

As a result of post-pandemic test normalization, increased outpatient volume, and the integration of advanced molecular and genomic assays into routine care, growth momentum continues to accelerate through 2024 and 2025. From 2026 onward, growth moderates toward 4 to 5%, in line with the updated forecast trajectory, as the industry settles around payer-driven usage restrictions and high-throughput efficiency. Although the Protecting Access to Medicare Act (PAMA) continues to exert price pressure, payer reimbursements are increasingly linked to clinical utility and test value. To preserve profits, this forces labs-especially those affiliated with hospitals and mid-tier regional players-to focus on operational scalability, test menu optimization, and digital workflow efficiency to run profitably.

Report Summary: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market was valued at USD 130.88 billion in 2024 and is projected to reach USD 175.13 billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. Market growth is driven by rising test volumes associated with an aging population, increasing prevalence of chronic diseases, and the expanding role of laboratory diagnostics in preventive and value-based care models.

Key Market Trends & Insights

• Independent and reference laboratories account for a significant share of testing volumes in the clinical laboratory services market, supported by national logistics networks and broad test menus.
• In the US Clinical Laboratory Services Market, demand for molecular diagnostics, oncology testing, and genetic assays is increasing alongside routine diagnostic testing.
• Automation, LIS-EHR integration, and AI-enabled workflow optimization are improving turnaround times and operational efficiency across large and mid-sized laboratories.
• The US Clinical Laboratory Service Market is experiencing continued consolidation as large national laboratories expand through acquisitions and hospital outreach partnerships.
• Retail clinics, mobile diagnostics, and home-based sample collection models are expanding patient access and convenience, supporting incremental test utilization.

Market Size & Forecast

• 2024 Market Size: USD 130.88 Billion
• 2030 Projected Market Size: USD 175.13 Billion
• CAGR (2024-2030): 5.0%
• United States: Single-country market with nationwide laboratory coverage

The continued reliance of the U.S. healthcare system on diagnostic testing, combined with technology adoption and service model innovation, is expected to support sustained growth in the U.S. Medical and Diagnostic Laboratory Services Market through the forecast period.

Market Overview & Trends: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market underpins nearly every clinical decision across the healthcare continuum. Laboratory testing supports screening, diagnosis, therapy selection, and disease monitoring, making the clinical laboratory services market indispensable to modern medicine. Demand continues to rise due to population aging, increasing chronic disease burden, and expanded utilization of diagnostic testing in value-based care models.

A major structural trend shaping the US Clinical Laboratory Services Market is the shift toward specialized and high-complexity testing. Molecular diagnostics, genomics, oncology assays, and companion diagnostics are increasingly used to guide personalized treatment strategies. While routine testing continues to provide volume stability, specialty diagnostics are driving incremental growth and clinical relevance.

Automation and digitalization are transforming laboratory operations. Advanced robotics, laboratory information systems (LIS), and artificial intelligence-enabled workflow tools are improving turnaround times and reducing labor dependency. These investments are particularly critical as workforce shortages persist across the U.S. Medical and Diagnostic Laboratory Services Market.

Another important trend is the centralization of testing. Independent and reference laboratories are capturing a growing share of outsourced testing volumes due to economies of scale and broad test menus. Consolidation enables cost efficiency but also intensifies competition within the US Clinical Laboratory Service Market.

Consumerization of healthcare is also influencing demand. Retail clinics, mobile diagnostics, and home-based sample collection are expanding access to routine testing and preventive care. These models complement traditional hospital-based services and reshape patient engagement across the clinical laboratory services market.

Overall, the market is evolving toward a more automated, data-driven, and patient-centric diagnostic ecosystem.

Scope of Analysis: U.S. Medical and Diagnostic Laboratory Services Market

This analysis examines the U.S. Medical and Diagnostic Laboratory Services Market, focusing on laboratory-based testing services delivered within the United States. The study evaluates diagnostic testing performed on blood, tissue, urine, and other biological specimens to support clinical decision-making across preventive, diagnostic, and therapeutic applications.

The scope includes hospital-based laboratories, independent and reference laboratories, physician office laboratories, and emerging retail and home-testing models. Both routine and specialized testing services are covered within the US Clinical Laboratory Services Market, while laboratory equipment manufacturing and reagent sales are excluded.

The study period spans recent historical years through 2030, with 2024 as the base year and 2030 as the forecast endpoint. Market sizing and forecasts are presented in U.S. dollars.

Methodologically, the analysis integrates secondary research, healthcare utilization data, regulatory review, and expert insights. Market forecasts reflect testing volume trends, reimbursement dynamics, and structural changes across the clinical laboratory services market. Segmentation-level revenue estimates are intentionally excluded to maintain analytical consistency.

Market Segmentation Analysis: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is segmented by service provider type and testing service category, reflecting the diverse operational models and clinical roles within the broader clinical laboratory services market.

Segmentation by Service Providers

By provider type, the US Clinical Laboratory Services Market comprises hospital-based laboratories, physician-owned laboratories (POLs), independent and reference laboratories, specialized laboratories, and other laboratory settings.

Hospital-based laboratories perform the highest volume of tests and are directly integrated into hospital systems, supporting inpatient care, emergency diagnostics, and complex clinical workflows. These laboratories are typically attached to large healthcare institutions and academic medical centers, enabling rapid turnaround times and close coordination with clinical teams.

Physician-owned laboratories (POLs) operate within physician offices and specialty practices such as urology, gynecology, and endocrinology. POLs represent the most common laboratory type by number, although they account for less than 10% of total test volumes. These facilities focus on low-volume, routine, and point-of-care tests that deliver immediate results. Larger POL networks often forward samples to centralized laboratories for advanced testing.

Independent, reference, and specialized laboratories operate across wide geographic regions and manage multiple laboratory facilities. Reference laboratories provide comprehensive test menus and handle high-throughput volumes, while specialized laboratories focus on advanced diagnostics such as oncology, genetics, and molecular testing. These providers play a central role in the US Clinical Laboratory Service Market, supporting outsourced testing for hospitals and POLs.

Other laboratories include retail clinics, mobile diagnostic centers, nursing homes, and home health agencies. These settings primarily support routine and preventive testing. Many services in this category are paid out-of-pocket and are not fully reimbursed under Medicare, contributing modestly to overall healthcare revenue.

Segmentation by Testing Services

By service type, the clinical laboratory services market is divided into routine testing services and specialized testing services.

Routine testing services include commonly performed diagnostic procedures such as blood chemistry panels, complete blood counts, and urine analysis. These tests form the backbone of diagnostic volume across the U.S. Medical and Diagnostic Laboratory Services Market.

Specialized testing services encompass high-end diagnostics such as cytogenetics, molecular diagnostics, next-generation sequencing (NGS), and whole-exome sequencing (WES). Semi-specialized services, including coagulation studies, autoimmune testing, and cancer biomarker assays, also fall within this segment. Growth in specialized testing reflects increasing demand for precision medicine and advanced clinical decision support.

Revenue & Spending Forecast: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market continues to evolve as automation, consolidation, and the shift toward value-based care reshape industry economics. According to the revenue forecast, the market generated USD 130.88 billion in 2024 and is projected to reach USD 175.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.0% during 2024-2030. This steady expansion underscores the essential role of laboratory testing in clinical decision-making across the U.S. healthcare system.

Revenue growth in the US Clinical Laboratory Services Market is supported by rising test volumes driven by an aging population, increasing prevalence of chronic diseases, and expanded utilization of diagnostic testing in preventive and longitudinal care. At the same time, the market is undergoing structural change as laboratories adapt to margin pressures resulting from PAMA-driven reimbursement reductions, rising labor costs, and tighter regulatory oversight of laboratory-developed tests (LDTs).

Large national and hospital-affiliated laboratories are increasingly expanding through mergers, digital integration, and AI-enabled process automation to improve operational efficiency and scale. Investments in automation, LIS-EHR integration, and advanced analytics are enabling providers to manage higher volumes while controlling costs. Additionally, new access channels-such as home-based diagnostics and consumer-oriented testing-are contributing to incremental revenue growth.

Overall, while the clinical laboratory services market remains high-volume in nature, revenue expansion is increasingly linked to payer alignment, operational scale, and technology adoption, positioning the US Clinical Laboratory Service Market for sustained growth through the end of the forecast period.

Growth Drivers: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is supported by multiple structural growth drivers that are expected to sustain demand through the forecast period. One of the most significant drivers is the rapid expansion of clinical informatics and healthcare data generation across early-stage research, clinical development, and commercial diagnostics. Growing data volumes are increasing the value of integrated diagnostics, predictive analytics, decision-support tools, and companion diagnostics (CDx), strengthening the role of laboratories in drug development and clinical trials.

Technology adoption within the clinical laboratory services market is accelerating as physician-owned laboratories (POLs) expand point-of-care testing (POCT) capabilities. At the same time, rising consumer interest in health IT solutions-such as telemedicine platforms, mobile health applications, and connected diagnostic devices-is driving demand for convenient, faster, and cost-effective testing services.

Another major growth driver is the continued expansion of next-generation sequencing (NGS)-based panels across infectious disease, oncology, and genetic testing. Improvements in payer coverage and declining test costs are enabling broader adoption of molecular pathology services at double-digit growth rates.

Operational investments are also reshaping the US Clinical Laboratory Services Market. Increased spending on robotics, LIS-EHR integration, and AI-driven automation is improving laboratory throughput while reducing turnaround times and workforce dependency. End-to-end digital workflows are becoming a priority for both hospital-based and reference laboratories.

Finally, ongoing reimbursement pressure under PAMA and bundled payment models is pushing laboratories toward higher-value, outcome-based service models. Industry consolidation and vertical integration, combined with the growth of at-home phlebotomy, mobile diagnostics, and retail testing partnerships, are further expanding access and driving sustained growth across the US Clinical Laboratory Service Market.

Growth Restraints: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market faces several structural restraints that may moderate growth through the forecast period. One of the most significant challenges is the implementation of the FDA's Final Rule on Laboratory Developed Tests (LDTs) in 2024. The regulation has increased compliance, validation, and documentation costs, disproportionately impacting small and specialized laboratories. While large reference laboratories may gain a relative advantage, academic and hospital-based labs face longer innovation cycles and delayed test adoption.

Workforce constraints remain a persistent restraint across the clinical laboratory services market. The United States continues to experience a shortage of qualified medical technologists due to underfunded training programs, high retirement rates, and limited new workforce entry. Rising burnout, overtime expenses, and staffing costs are restricting growth, particularly for hospital-based laboratories. Although automation and outsourcing provide partial relief, they do not fully offset labor shortages.

Capital intensity represents another key challenge. Clinical laboratories must continuously invest in analyzers, automation platforms, and IT infrastructure. Smaller and mid-tier laboratories face low margins, extended return-on-investment periods, and limited access to funding, pressures that are amplified by inflation and declining reimbursement rates.

In addition, slow adoption of advanced analytics and automation persists despite mandatory EHR integration. Interoperability issues, fragmented middleware systems, data silos, and cybersecurity risks continue to limit operational efficiency. The absence of standardized test ordering and data exchange protocols further increases administrative burdens, leading to billing delays, claim rejections, and compliance penalties across multi-payer and multi-state laboratory networks.

Competitive Environment: U.S. Medical and Diagnostic Laboratory Services Market

The U.S. Medical and Diagnostic Laboratory Services Market is characterized by a highly fragmented yet consolidating competitive environment, comprising approximately 1,500 CLIA-certified laboratories nationwide. These include regional and national independent laboratories, hospital outreach programs, reference laboratories, and specialty testing providers. Competition within the US Clinical Laboratory Services Market is driven by scale, regulatory compliance, service breadth, and operational efficiency.

Key competitive factors shaping differentiation across the clinical laboratory services market include compliance with CLIA and CAP standards, payer reimbursement rates, test accuracy, turnaround time, cost effectiveness, and the breadth of test menus. Integration with electronic health record (EHR) systems and the ability to realize consolidation synergies through acquisitions also play a critical role in competitive positioning, particularly for large national providers.

End-user verticals span hospital-based laboratories, physician-owned laboratories (POLs), independent and reference laboratories, and specialized testing providers. Additional demand is generated by retail clinics, mobile diagnostic centers, nursing homes, and home health agencies, all of which are increasingly integrated into care delivery models across the US Clinical Laboratory Service Market.

The competitive landscape is led by large national and specialty players, including Labcorp, Quest Diagnostics, Exact Sciences, Natera, Sonic Healthcare USA, Myriad Genetics, Guardant Health, Mayo Clinic Laboratories, and ARUP Laboratories. Collectively, the top five independent reference laboratories (IRLs) accounted for an estimated 46.3% of total U.S. clinical laboratory services revenue in 2024, highlighting increasing concentration at the top end of the market.

Other notable participants include BioReference Laboratories, Northwell Health Labs, PathGroup, Aegis Sciences, as well as academic hospital networks such as Cleveland Clinic and Johns Hopkins.

Distribution across the U.S. Medical and Diagnostic Laboratory Services Market combines hospital-based networks, centralized reference laboratories, and expanding courier and digital logistics infrastructure for specimen collection. In 2024, Quest Diagnostics acquired select laboratory assets from Allina Health, enhancing access to laboratory services across Minnesota and western Wisconsin and underscoring ongoing consolidation trends within the market.

Table of Contents

Growth Opportunities: Research Scope

• Scope of Analysis
• Segmentation
• The Role of Clinical Laboratory Services in Healthcare
• Holistic Business Model-Laboratories as 1-Stop-Shop Service Providers
• Innovations Enhancing Clinical Laboratory Services

Growth Environment: Transformation in United States Clinical Laboratory Services Industry

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the United States Clinical Laboratory Services Industry

Ecosystem in United States Clinical Laboratory Services Industry

• Competitive Environment

Growth Generator in United States Clinical Laboratory Services Industry

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Service Providers
• Revenue Forecast Analysis by Service Providers
• Revenue Forecast by Services
• Revenue Forecast Analysis by Services
• US Clinical Laboratory Services Pricing Analysis
• US Clinical Laboratory Services Pricing Analysis by Application, 2024
• US Breakdown of Application Shares in Laboratory Services
• United States Key Regulatory and Reimbursement Environment Developments 2020-2025
• United States Regulatory Landscape Analysis-2024 Onwards
• US Health Insurance Landscape-2024 Overview
• Medicare and Medicaid Spending on Hospital Care
• Revenue Share
• Revenue Share Analysis-Competitor
• Revenue Share by Type of Payer in IRLs
• Competitive Landscape, Top Players Offering Parameters
• Notable Activities

Growth Opportunity Universe in United States Clinical Laboratory Services

• Growth Opportunity 1: Specialized and Advanced Testing Beyond Acute and Oncology Testing
• Growth Opportunity 2: Decentralized and Home-Based Diagnostics Ecosystem for Enhanced Access and Speed
• Growth Opportunity 3: AI-Driven Digital Pathology and Workflow Automation for High-Volume Diagnostics

Appendix & Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer